Zepbound approved for obstructive sleep apnoea
A discrete diagnosis with an approved indication is a stronger prior-authorisation argument than a BMI threshold.
Released: · Last reviewed:
A discrete diagnosis with an approved indication is a stronger prior-authorisation argument than a BMI threshold.
Approval covers moderate-to-severe OSA in adults with obesity, on the strength of a trial showing large reductions in apnoea-hypopnoea index at 52 weeks with and without CPAP.
If you have suspected sleep apnoea and are paying cash, a sleep study is the highest-value thing you can do about your bill.
What this changes for what you pay
Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement, the pharmacy licensing framework or the clinical review behind a prescription.
Month-to-month all-in prices at 10 mg among the programs we track start at $129 (Eden Health, read October 15, 2026; NexLife charges the same as of November 6, 2026). Where a development moves that figure, our tables move with it on the next build.
How to verify this yourself
Regulatory claims should be checked against the agency rather than against coverage of the agency. FDA publishes warning letters searchable by company name, a shortage database, and its compounding pages. Trial claims should be checked against the registry entry rather than a press release.
Every source behind this item is linked below, and where a story is still moving we say so rather than implying it is settled.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.